It's little secret that pharmaceutical giant Eli Lilly (NYSE:LLY) faces drug patent expirations on its top-selling drugs over the next few years. The question is the extent to which this is already reflected in the share price and whether the company can find a way to put billions in cash flow to good use and find a way out of its predicament.
IN PICTURES: 9 Ways To Use A Tax Refund

First-Quarter Highlights
Total sales advanced a healthy 9% to $5.5 billion as LLY's four highest-grossing drugs - Zyprexa, Cymbalta, Alimta, and Humalog - all reported strong top-line trends. Zyprexa, which is used primarily for the treatment of schizophrenia and bipolar disorders, accounts for 22.1% of sales and saw an 8% boost while the rest of the top four experienced double-digit increases.

Reported net income fell 5% to $1.25 billion, or 23.6% of sales, as cost of sales and income taxes rose by more than 30%. Higher shares outstanding sent earnings down 2% to $1.18 per diluted share. However, the company's definition of operating earnings resulted in 8% growth and didn't include charges related to expected health care reform costs in coming years and a number of other small non-recurring expenses.

Health care reform costs also resulted in the lowering of company full-year earnings guidance to between $4.35 and $4.50 per share. Management expects 35 cents in charges from the reforms and mid-single digit sales growth on volume increases on most of its top-selling drugs as well as Cialis and Effiant. (Learn about the controversies surrounding companies commenting on their forward-looking expectations in Can Earnings Guidance Accurately Predict The Future?)

Bottom Line
Lilly's quarterly profits came in ahead of analyst expectations and based off earnings guidance the company is trading at a seemingly bargain-basement forward P/E multiple of under nine. However, 2011-2013 will see close to have of sales fall victim to generic competition from the likes of TEVA Pharmaceuticals (Nasdaq:TEVA) and Mylan (NYSE:MYL) and includes patent expiration of Zyprexa and Cymbalta, Lilly's two top sellers.

Lilly, along with Forest Labs (NYSE:FRX), has so far chosen to go it alone in developing new drugs to replace those with expiring patents. This is in contrast to other industry leaders, including Merck (NYSE:MRK) that has chosen to also pursue mergers to diversify away from drugs losing patent protection. The go-it-alone bias is risky, but the low earnings multiple offers a good degree of downside protection. And in the case of Lilly it will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  2. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  3. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  4. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  5. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  6. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  7. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  8. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  9. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  10. Investing News

    Corporate Bonds or Stocks: Which is Better Now?

    With market volatility high, you may think it is time to run for corporate bonds instead of stocks. Before you do take a deeper look into which is better.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!